Epigenomics Market Size, Share and Global Trend By Product Type (Reagents, Kits, Enzymes), By Technology (DNA Methylation, Histone Methylation, Histone Acetylation, MicroRNA Modification, Large Non-coding RNA, Chromatin Structures), By Application (Pharmaceutical, Diagnostics)Regional Forecast, 2024-2032

Epigenomics refers to the analysis of modifications to the DNA and DNA related any other protein in the cell. Cancer which is considered as one of the most common condition has emerged as one of the major application area for epigenomics. This has initiated the introduction of many drugs based on epigenomics techniques in the market and have also encouraged many prominent players to carry clinical research either through strategic collaboration or public-private partnership models. The completion of the Human Genome Project and the growing focus towards personalized medicines have geared up the research for the development of therapies using epigenomics.

Using the concept of epigenetics, Canadian Cancer Trials Group is conducting research on HDAC inhibitor SB939 for treatment of prostate cancer. The emergence of epigenetics is expected to revolutionize the methods used for the treatment of cancer. Similarly, in January 2017, Illumina Inc., collaborated with Koninklijke Philips N.V., for analysis of genetic variation and developing integrated genomics solution for cancer. By developing modulators through methods such as DNA methylation, histone acetylation, histone methylation, and many other novel therapies can be made possible for cancer. 

The increased funding for research in the field of epigenomics, new product launch, greater adoption of epigenomics methods based kits and microarray for diagnosis and increased in clinical trials to use epigenetics modulators to treat cancer are the primary reasons attributed for the growth in epigenomics market. 

Furthermore, the fast pacing shift toward personalized medicine as it patient specific is anticipated to accelerate the growth in global epigenomics market during the projected years. However, lack of skilled professional in emerging countries and stringent government regulations are factors that can hamper the growth in global epigenomics market. 

Key Players Covered 

Some of the major companies that are present in the global epigenomics market Novartis AG, Abbott Laboratories, Abcam plc, Merck KGaA, Thermo Fisher Scientific Inc., Zymo Research Corporation, Illumina Inc., Agilent Technologies Inc., Epizyme Inc., Boehringer Ingelheim International GmbH, Bayer AG, Epigenomics, and other players. 

 SEGMENTATION

The pharmaceutical segment is likely to dominate the global epigenomics market owing to the rising prevalence of diseases especially cancer and increase in research to exploit epigenetics alteration for the treatment of cancer. According to WHO, the number of cancer cases in the world by 2025 is estimated to be 21,471,996, encouraging researchers to develop novel epigenomics modulators for treatment, augmenting the growth in the pharmaceutical segment in global epigenomics market 

Key Insights 

• Epidemiology of cancer-key countries, 2017
• Pipeline analysis
• Regulatory scenario for key countries
• Overview of government research grants
• Key mergers and acquisitions 

Regional Analysis 

The global epigenomics market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. The global epigenomics market is expected to have an exponential growth in North America in the forecast years owing to the huge R&D investment and introduction of new product into the market. In Europe growth in epigenomics market is estimated to propel by the end of 2025 due to the strategic collaborations and active government support for the development of novel therapy for cancer. In 2018, Boehringer Ingelheim International GmbH, a pharmaceutical company partnered with Epizyme Inc., for research and development of novel molecule inhibitors to treat cancer, which is further expected to fuel the epigenomics market in Europe. 

Key Industry Developments

• In December 2018, Epigenomics AG, a molecular diagnostic company initiated a study on cell free methylated DNA biomarker for the detection of hepatocellular carcinoma (HCC) in patients having cirrhosis.
• In November 2018, Boehringer Ingelheim International GmbH, a pharmaceutical company partnered with Epizyme Inc., research and development novel molecule inhibitors to treat cancer.
• In July 2017, Agilent Technologies, Inc. launched Real-Time PCR System in Europe for clinical diagnostics.
• In January 2017, Illumina Inc., collaborated with Koninklijke Philips N.V., for analysis of genetic variation and developing integrated genomics solution for cancer.